Establish A National Real-World Decentralized COVID-19 Program Targeting Ivermectin, Fluvoxamine, Colchicine, Famotidine & Nitazoxanide

Establish A National Real-World Decentralized COVID-19 Program Targeting Ivermectin, Fluvoxamine, Colchicine, Famotidine & Nitazoxanide

Two prominent researchers affiliated with Emory University, including a Professor of Medicine and Dean of the School of Medicine and Chief Academic Officer of this preeminent university, remind readers recently in Health Affairs that although COVID-19 cases are now on the decline, 3,000 Americans die every day while more contagious and possibly dangerous mutant strains circulate around North America now, again keeping health systems on the precipice. While the authors express overall confidence in the global drug and vaccine development imperative, they warn that mass vaccination impact won’t evidence palpable positive results until at least mid-2021. Moreover, they are mindful that these vaccines are still experimental (under emergency authorization) and many outstanding questions remain unanswered—such as how long they are impactful. Vikas Sukhatme and Vidula Sukhatme boldly declare more must be done, and now. That is, a plan to potentially save up to 150,000 lives over the next few months. Listen to their proposal—use repurposed drugs in a national decentralized real-world program, while monitoring the ongoing real world data. Only an easy to administer, affordable, scalable, a...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee